Market Cap | 45.43M | P/E | - | EPS this Y | 18.30% | Ern Qtrly Grth | - |
Income | -157.32M | Forward P/E | -0.33 | EPS next Y | 11.70% | 50D Avg Chg | 7.00% |
Sales | 10.34M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -61.00% |
Dividend | N/A | Price/Book | 2.07 | EPS next 5Y | - | 52W High Chg | -95.00% |
Recommedations | 3.00 | Quick Ratio | 1.04 | Shares Outstanding | 151.68M | 52W Low Chg | 69.00% |
Insider Own | 42.91% | ROA | -81.78% | Shares Float | 68.10M | Beta | 1.44 |
Inst Own | 26.85% | ROE | -366.87% | Shares Shorted/Prior | 1.03M/3.37M | Price | 0.30 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 694,430 | Target Price | 0.60 |
Oper. Margin | -1,493.50% | Earnings Date | Aug 14 | Volume | 143,167 | Change | 0.00% |
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company's plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae. It also developing fungicides program for botrytis, fusarium, powdery mildew, downy mildew, Asian soybean rust, and rice blast; Gray Mold + for botrytis cinerea; Powdery mildew complex for the control of powdery mildew, caused by Erysiphe necator; and Mycotoxin control for Fusarium Head Blight, a cereal crop based diseases. In addition, the company also developing human health program comprising a phase I/II preclinical stage vaccine for COVID-19; and candidate selection vaccines for Shingles, and oncology. GreenLight Biosciences Holdings was formerly known as Environmental Impact Acquisition Corp. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Canaccord Genuity | Hold | May 31, 23 |
Canaccord Genuity | Buy | Dec 8, 22 |
Credit Suisse | Outperform | Oct 14, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Ortega-Valle Marta | Chief Business Offic.. Chief Business Officer | Jun 01 | Option | 0.23 | 29,798 | 6,854 | 29,798 | 09/07/22 |
Morningside Venture Investment... | 10% Owner 10% Owner | Aug 11 | Buy | 3.92 | 3,061,224 | 11,999,998 | 15,919,155 | 08/15/22 |
Builders Vision, LLC | 10% Owner 10% Owner | Aug 11 | Buy | 3.92 | 6,505,102 | 25,500,000 | 22,348,123 | 08/15/22 |
Walker Matthew Allen | Director Director | Aug 11 | Buy | 3.92 | 6,441,326 | 25,249,998 | 22,220,572 | 08/15/22 |
Walker Matthew Alan | Director Director | Feb 02 | Buy | 10 | 1,500,000 | 15,000,000 | 15,843,021 | 02/04/22 |